Worth reading
44Recurring
Scored from 4 of 5 sectionsDirection
Neutral
Direction inferred from the company’s description.Scale
6300
Shares (63 stock acquisition rights × 100 shares per right)Wording
Definitive
How definitive the wording is.Details of issuance or disposal
Issuance of stock acquisition rights as stock compensation-type stock options (Series 19 stock acquisition rights)
Who receives how much
6,300 common shares (63 stock acquisition rights, 100 shares per right)
4 directors of the Company; allocation by number of shares: 非開示
The lower thin line represents the existing number of shares to which these shares will be added.
Fair value for accounting purposes as of the allotment date
Amount of funds to be raised
No payment is required. Estimated net proceeds: Not disclosed
Total Stock-Based Compensation
The amount corresponding to the fair value for accounting purposes as of the allotment date. The specific amount is Not disclosed
Terms of the stock acquisition rights
Exercise price
¥1 per share. If the number of shares is adjusted, the exercise price will be adjusted in accordance with the adjusted number of shares.
Exercise period
From 21 July 2026 to 20 July 2041
Number of Stock Acquisition Rights
Total issued: 63 stock acquisition rights. Number of unexercised rights: Not disclosed
Reason for acquisition without consideration
The rights will lapse upon expiration of the exercise period or 5 years after retirement from office. The Company may acquire the rights without consideration if the Board of Directors resolves to do so in cases including a material violation of laws or internal rules, or appointment as an officer or employee of a competing company.
Conditions on transfer restrictions
Restricted stock is stock awarded as compensation that cannot be sold during a specified period, with the restrictions lifted once the applicable conditions are met.
Conditions for lifting transfer restrictions
The holder must be a director or audit & supervisory board member of the Company at the time of exercise. However, the rights may be exercised within 5 years after retirement from office.
Categories and Number of Persons Covered
4 directors of the Company. The number of shares allotted to each individual is Not disclosed
Intended allottee's holding policy
Transfer and pledging of the stock acquisition rights are prohibited. In the event of death, the rights may be inherited by only 1 statutory heir.
Payment date
Not applicable (no cash payment is required in exchange for the stock acquisition rights)
Basis for determining the amount to be paid
The issue price will be the fair value for accounting purposes as of the allotment date. The closing price and average share price used as benchmarks, and the discount and premium rates, are Not disclosed
Procedures under the Corporate Code of Conduct
Based on the provisions of Articles 361, 236, 238 and 240 of the Companies Act and the approval granted at the Board of Directors meeting held on 21 May 2025, the specific terms of issuance were determined at the Board of Directors meeting held on 27 April 2026.
Impact on Business Performance
The purpose is to strengthen the linkage between directors’ compensation and the Company’s performance and share value, and to enhance directors’ motivation and morale to achieve sustained performance improvement and increase corporate value over the medium to long term.
| Item | Details |
|---|---|
| Type of issuance or disposal | Issuance of stock acquisition rights as stock compensation-type stock options (Series 19 stock acquisition rights) |
| Number of shares to be issued or disposed of | 6,300 common shares (63 stock acquisition rights, 100 shares per right) |
| Issue price and disposal price | Fair value for accounting purposes as of the allotment date |
| Amount of funds to be raised | No payment is required. Estimated net proceeds: Not disclosed |
| Payment date | Not applicable (no cash payment is required in exchange for the stock acquisition rights) |
| Intended allottee | 4 directors of the Company; allocation by number of shares: Not disclosed |
| Intended allottee's holding policy | Transfer and pledging of the stock acquisition rights are prohibited. In the event of death, the rights may be inherited by only 1 statutory heir. |
| Basis for determining the amount to be paid | The issue price will be the fair value for accounting purposes as of the allotment date. The closing price and average share price used as benchmarks, and the discount and premium rates, are Not disclosed |
| Exercise price | ¥1 per share. If the number of shares is adjusted, the exercise price will be adjusted in accordance with the adjusted number of shares. |
| Exercise period | From 21 July 2026 to 20 July 2041 |
| Number of Stock Acquisition Rights | Total issued: 63 stock acquisition rights. Number of unexercised rights: Not disclosed |
| Conditions for lifting transfer restrictions | The holder must be a director or audit & supervisory board member of the Company at the time of exercise. However, the rights may be exercised within 5 years after retirement from office. |
| Reason for acquisition without consideration | The rights will lapse upon expiration of the exercise period or 5 years after retirement from office. The Company may acquire the rights without consideration if the Board of Directors resolves to do so in cases including a material violation of laws or internal rules, or appointment as an officer or employee of a competing company. |
| Categories and Number of Persons Covered | 4 directors of the Company. The number of shares allotted to each individual is Not disclosed |
| Total Stock-Based Compensation | The amount corresponding to the fair value for accounting purposes as of the allotment date. The specific amount is Not disclosed |
| Procedures under the Corporate Code of Conduct | Based on the provisions of Articles 361, 236, 238 and 240 of the Companies Act and the approval granted at the Board of Directors meeting held on 21 May 2025, the specific terms of issuance were determined at the Board of Directors meeting held on 27 April 2026. |
| Impact on Business Performance | The purpose is to strengthen the linkage between directors’ compensation and the Company’s performance and share value, and to enhance directors’ motivation and morale to achieve sustained performance improvement and increase corporate value over the medium to long term. |
Items this document does not state (11)
Total issue valueEstimated issuance expensesSpecific use of fundsDilution RateTotal number of issued sharesTransfer restriction periodUnderwriter / lead underwriterOverallotmentStock Split RatioMost recent equity financingMajor shareholders after the offering
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.To strengthen the linkage between directors’ compensation and the Company’s performance and share value, and to share with shareholders the benefits of a rising share price and the risks of a falling share price, thereby enhancing directors’ motivation and morale to improve performance and increase corporate value over the medium to long term.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.